Researchers have been exploring new ways to tackle multiple myeloma, a challenging condition to treat. A recent study involves using liposomes loaded with bortezomib, a proteasome inhibitor, to target bone marrow. This approach aims to overcome resistance in multiple myeloma, which is known for its persistent progression and low survival rates Menachem et al. (2025). Bortezomib is a drug that helps break down proteins inside cells, which can help stop cancer cells from growing.
The use of targeted liposomes could potentially improve the delivery of bortezomib directly to the bone marrow, where multiple myeloma cells reside. This targeted approach might enhance the effectiveness of the treatment while reducing side effects. While the study's details are not fully disclosed, it suggests a promising direction in addressing the challenges of treating multiple myeloma, which often involves finding ways to improve drug delivery and efficacy.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar